Surrozen, Inc.
SRZNW
NASDAQ Capital Market0.02
USD
-NaN
- -
CIK
0001824893
ISIN
US86889P1176
CUSIP
86889P117
Return %
Stock
S&P500
1Y
-35.61
26.53
3Y
-73.72
76.60
5Y
-98.72
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Craig C. Parker
- Full Time Employees
- 40
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 171 Oyster Point Boulevard South San Francisco CA United States of America 94080
- IPO Date
- Aug 10, 2021
- CIK
- 0001824893
- Website
- surrozen.com
- Similar Companies
- Business
- Surrozen, Inc. (Nasdaq: SRZN) Surrozen, Inc. is a clinical-stage biotechnology company that discovers and develops antibody-based therapeutics to selectively modulate the Wnt signaling pathway for tissue repair and regeneration, with a current focus on ophthalmology programs targeting severe eye diseases such as diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), uveitic macular edema (UME), Fuchs’ endothelial corneal dystrophy, geographic atrophy, and retinal vascular-associated diseases. Its core pipeline includes wholly-owned candidates SZN-8141, combining Frizzled 4 (Fzd4) agonism and vascular endothelial growth factor (VEGF) antagonism; SZN-8143, combining Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism; and SZN-113 for corneal and retinal conditions; as well as SZN-413, a Fzd4-targeted bispecific antibody licensed to Boehringer Ingelheim International GmbH for retinal diseases. The company leverages proprietary technologies including SWAP (Surrozen Wnt Antibody Platform) to engineer tissue-specific antibodies that engage the body's repair mechanisms across potential applications in intestine, liver, lung, kidney, cochlea, skin, pancreas, and central nervous system diseases. In March 2025, Surrozen announced a strategic pivot to prioritize its ophthalmology pipeline, securing an oversubscribed $175 million private placement financing led by Venrock Healthcare Capital Partners with participation from investors including The Column Group, RA Capital Management, and Vivo Capital to fund Phase 1 studies of SZN-8141 and SZN-8143, with the second tranche of $105 million contingent on FDA clearance for SZN-8141's Investigational New Drug application expected in 2026. Concurrently, the company discontinued development of SZN-043 for severe alcohol-associated hepatitis due to insufficient early clinical benefit signals despite demonstrated safety. Existing collaborations include a 2022 license agreement with Boehringer Ingelheim for SZN-413 and certain Fzd4 bi-specific antibodies, providing up to $587 million in milestones plus royalties, and a research collaboration with TCGFB, Inc. for TGF-β-targeted antibodies in pulmonary fibrosis, which was terminated effective November 13, 2025. Founded in 2015 and headquartered at 171 Oyster Point Boulevard, Suite 400, South San Francisco, California, Surrozen operates primarily in the United States and targets patients with high-unmet-need regenerative medicine indications through its Wnt pathway expertise.